Rigel CFO awarded options on 7,394 shares

Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported the acquisition of an employee stock option covering 7,394 shares of common stock.

Rhea-AI Filing Summary

Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported the acquisition of an employee stock option covering 7,394 shares of common stock. The option was originally granted on January 29, 2025 with an exercise price of $22.49 per share.

The award carried a performance-based vesting condition and was not reportable until that metric was satisfied. On June 17, 2026, the company determined the performance metric had been met, and the option became fully vested, leaving Schorno with 7,394 option shares following the transaction.

Insider Trade Summary

Grant/Award: 7,394 shares

Grant/Award 1 txn

Insider Schorno Dean L

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	7,394	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 7,394 contracts (Direct)

Footnotes (2)

1. F1. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
2. F2. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

Key Figures

Option shares granted: 7,394 shares Exercise price: $22.49 per share Grant date: January 29, 2025 +3 more

6 metrics

Option shares granted 7,394 shares Employee stock option tied to Rigel common stock

Exercise price $22.49 per share Closing price on Nasdaq on January 29, 2025

Grant date January 29, 2025 Date the performance-based stock option was granted

Vesting determination date June 17, 2026 Date performance metric was determined to be met

Expiration date January 29, 2035 Scheduled expiration of the option award

Shares after transaction 7,394 option shares Total related to this award following the transaction

Key Terms

performance-based condition, exercise price, Section 16, fully vested, +1 more

5 terms

performance-based condition financial

"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares"

exercise price financial

"The exercise price of this option is $22.49, which is the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Section 16 regulatory

"this grant was not reportable under Section 16 until the performance metric was satisfied"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

fully vested financial

"The option was fully vested on June 17, 2026, the date the determination was made"

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rigel Pharmaceuticals (RIGL) report for Dean L. Schorno?

Rigel Pharmaceuticals reported that EVP & Chief Financial Officer Dean L. Schorno acquired an employee stock option for 7,394 shares of common stock. The filing records this award once its performance-based vesting condition was met and the option became fully vested.

What are the key terms of Dean Schorno’s Rigel (RIGL) stock option grant?

Dean Schorno’s option covers 7,394 shares of Rigel common stock at an exercise price of $22.49 per share. The option was granted on January 29, 2025 and is scheduled to expire on January 29, 2035, subject to its terms.

When did the performance condition vesting Dean Schorno’s Rigel (RIGL) options get satisfied?

The performance metric for Dean Schorno’s option was determined to be met on June 17, 2026. On that date, the option became fully vested, triggering the reporting obligation under Section 16 for this performance-based stock option award.

Why was Dean Schorno’s Rigel (RIGL) stock option not reported earlier under Section 16?

The option carried a performance-based vesting condition, so it was not reportable under Section 16 until the performance metric was satisfied. Once the company determined the metric was achieved on June 17, 2026, the now-vested option award was reported.

How many Rigel (RIGL) option shares does Dean Schorno hold from this award after the transaction?

Following this reported transaction, Dean Schorno holds 7,394 option shares tied to this specific award. These options relate to Rigel common stock and reflect the entire amount associated with the performance-based grant described in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schorno Dean L

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$22.49(1)	06/17/2026		A		7,394(1)		(2)	01/29/2035	Common Stock	7,394(1)	$0	7,394	D

Explanation of Responses:

1. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

2. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

	/s/ Raymond Furey (Attorney-in-Fact)	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)